After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

Obesity, it says, isn’t just the outcome of ghee-laced parathas and Netflix binges. It’s a chronic condition shaped by genes, ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug Wegovy gains steam in the obesity space. But Wall Street wiped out more ...

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS) Foundation for STEM ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year. The ...